, 82 children with T leukaemia/lymphoma entered a randomised trial of combination chemotherapy and radiotherapy. Twenty-five were designated T lymphoma and 57 T leukaemia, 28 having > 100 x 1091 1 blasts in peripheral blood at diagnosis. Twenty-seven patients with mediastinal primaries who were treated on the companion non-Hodgkin lymphoma (NHL) trial were comparable in all respects to the T lymphoma patients and the results of treatment were therefore combined and analysed together. Overall 4-year survival (48-53%) and failure-free survival (FFS) (37-40%) were similar in all groups except the 28 with T leukaemia and WCC>100 x 10 1-1 (20% and 13%). There was a significant advantage in FFS for patients randomised to receive low dose mediastinal radiation, and this was most marked in patients with T lymphoma (66% vs 18%, P=0.006).
One of the most important advances in our understanding of the leukaemias and lymphomas of childhood has been the recognition that they are biologically a heterogeneous group of disorders.
Ten to 20% of children with a morphological diagnosis of acute lymphoblastic leukaemia (ALL) have lymphoblasts whose surface receptors indicate a T cell lineage, and these patients have an inferior prognosis when compared to patients with common ALL (Chessells et al., 1977) . About one-third of children with NHL present with a mediastinal mass and the lymphoblasts from these lymphomas likewise indicate a T cell lineage. The natural history of T cell lymphoma is for almost universal progression to involvement of the bone marrow and CNS (Watanabe et al., 1973) and it is highly likely that T cell lymphoma and T cell leukaemia are, in fact, different stages in the evolution of one disorder. There are minor differences in the phenotype of lymphoblasts in T lymphoma and T leukaemia (Roper et al., 1983 ) but nothing to indicate that they should not be regarded as essentially the same disease.
therapy to sites of bulk disease and an intensive multi-agent chemotherapy programme initially designed for the treatment of childhood ALL, but with the addition of early cyclophosphamide (the LSA2-L2 protocol), resulted in a dramatic improvement in the prognosis for childhood nonHodgkin lymphoma (NHL), particularly for those patients who presented with a mediastinal mass (Wollner et al., 1976) . In 1977, therefore, six of the centres within the UK Children's Cancer Study Group decided to submit all patients with either T lymphoma or T leukaemia to an intensified variant of our NHL protocol (Mott et al., 1984) , the design of which is in some respects similar to the LSA2-L2 regimen.
Patients and methods
The treatment protocol
The NHL protocol, previously described 1984 total of 7 doses of intrathecal methotrexate, 10 mg m2 (maximum 12 mg) during the induction and consolidation phases. The maintenance treatment was identical to that for patients with mediastinal primaries on the NHL trial, with oral rather than i.v. methotrexate because of previous cranial radiation, and was continued to complete 2 years of chemotherapy.
Patient entry
From November 1977 to July 1983 82 patients with T leukaemia/lymphoma entered this study. There were 65 boys and 17 girls (ratio 4:1) with an age range of 13 months to 15 years. Sixteen had no evidence of bone marrow involvement on either aspirate or trephine biopsy, and 9 had evidence of infiltration of the bone marrow but with <25% blasts. These 25 patients were designated as having had T lymphoma. Fifty-seven patients had more than 25% T lymphoblasts in bone marrow and/or T lymphoblasts in peripheral blood, and were designated as having had T leukaemia; 28 of these 57 had >100 x I091 1 blasts in peripheral blood.
There were 27 NHL patients presenting with a mediastinal mass who were treated in the parent NHL trial (Mott et al., 1984) . Careful comparison has shown no difference between clinical features at presentation or results of treatment in these patients and the 25 patients treated at 6 centres for T lymphoma in the T cell trial. Therefore for some analyses these two groups of patients with T lymphoma (total 52 patients) were combined.
The methodology used to establish T cell marker status has been described previously (Greaves et al., 1981; Habeshaw, 1980 presenting peripheral blasts <100 x O9 1, but those with >100xlOi-' blasts did much worse (Figure 3) , the difference in survival at 4 years being highly significant (P = 0.003).
There were 66 adverse initial events (Table II) 
Discussion
The poor prognosis for T cell disease was firmly established when the advent of cell surface marker Figure 4 Failure-free survival for T lymphoma patients randomised + mediastinal radiation ( x RT). Figure 5 Overall survival (...) and failure-free (-) survival for 52 patients with T lymphoma. Figure   4 ).
Review of the first adverse events occurring in these patients shows that the major differences between the two arms of the trial are in the frequency of spread to bone marrow and/or CNS (2 vs 10, Table III ) and in the late occurrence of relapse in the non-radiated patients (Figure 4 ). Late relapses up to five years from diagnosis were recorded in a pilot version of this protocol (Levine et al., 1983) and for this reason publication of the results has been delayed to a later stage than in many otherwise comparable studies. A number of those other studies did nevertheless appear to show the establishment of a plateau for survival of T lymphoma after about two years for patients given intensive combination chemotherapy, usually combined with radiation (Duque-Hammershaimb et al., 1983; Anderson et al., 1983; Reihm, 1983) .
In our trial where entry was confined to patients with T cell disease, the universal previous finding of a worse prognosis for leukaemic patients with a high initial blast count was again confirmed. The division between favourable and unfavourable prognosis is, however, not set where the arbitrary distinction is drawn between lymphoma and leukaemia (presence of 25% blasts in bone marrow) but is most obvious for T leukaemia patients who present with > 100 x iO91-1 blasts in peripheral blood. Compared with our past experience there has been a shift of the overall survival curve to the right and a corresponding increase in median survival time (24 months for all T leukaemias, 21 months for the high risk group), but late relapses and deaths have brought the plateau of the curve to well below 50%. The median FFS of 16 months for T leukaemia in our study compared favourably with the 13 month figure for a comparable group of patients treated on the POG 7615 study (Pullen et al., 1982) . The relative effectiveness of chemotherapy has enabled us to show that the randomised addition of low dose radiation to the mediastinum can increase the survival rate of some patients, particularly those with relatively localised disease (T lymphoma). This effect was not detected in the companion NHL trial where the FFS curve reached a plateau at a higher and earlier stage, possibly because of the different natural history of B lymphomas (Mott et al., 1984) . Review of the failures in the T cell trial suggests that the benefit observed from radiation would not be seen if given in conjunction with more effective systemic chemotherapy. The clinical features which distinguish patients with T ALL from "Common" ALL (c ALL) are now well established. The disease tends to occur in older children, with a marked predilection for males, and usually presents with a mediastinal mass, a high peripheral blast count and also a relatively high haemoglobin and platelet count. Patients with T ALL have a higher rate of relapse both early and late in the illness than do patients with c ALL. They also have a marked predisposition to involvement of CNS and other sites of extramedullary disease, such as the testes, both at diagnosis and during the evolution of the disease. Controversy continues about the relative significance of particular prognostic factors such as the initial blast count and the cell phenotype, and the findings are likely to vary between different treatment regimens until more effective treatment is established.
